Mira Pharmaceuticals (MIRA) Change in Receivables (2024)
Mira Pharmaceuticals' (MIRA) quarterly Change in Receivables came in at -$11862.0 in Q1 2024.
Mira Pharmaceuticals (MIRA) Change in Receivables (2024) Analysis & Trends
Mira Pharmaceuticals has disclosed Change in Receivables across 1 years of filings, most recently posting -$11862.0 for Q1 2024.
- Change in Receivables for Q1 2024 came in at -$11862.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was -$11862.0 (changed N/A YoY), and the FY2024 annual result was -$11862.0, down 200.0% from the prior year.
- Change in Receivables came in at -$11862.0 for Q1 2024 at Mira Pharmaceuticals.
- In the past five years, Change in Receivables ranged from a high of -$11862.0 in Q1 2024 to a low of -$11862.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Mira Pharmaceuticals | 22.73 Mn | 11.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -11,862.00 |
| Mar 31, 2024 | -11,862.00 |